# Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

> **NCT06324994** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Dalian Medical University** · enrollment: 10 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Linperlisib in combination with Obinutuzumab and Venetoclax

## Key facts

- **NCT ID:** NCT06324994
- **Lead sponsor:** Dalian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06324994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06324994, "Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06324994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*